Axial Spondyloarthritis – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
The axial spondyloarthritis (AxSpA) treatment landscape consists of biologics from two established classes: TNF-α inhibitors (Amgen/Pfizer’s Enbrel, AbbVie’s Humira, Johnson & Johnson Innovative Medicine’s Remicade and Simponi/Simponi Aria, and UCB’s Cimzia) and IL-17 inhibitors (Novartis’s Cosentyx, Eli Lilly’s Taltz, and UCB’s Bimzelx). TNF-α inhibitors are widely used after inadequate response to NSAIDs, although their role has shifted with the availability of cost-effective biosimilars and increasing use of IL-17 inhibitors. Since UCB’s Cimzia became the first FDA-approved therapy for non-radiographic AxSpA (nr-AxSpA) in 2019, treatment options have expanded to include IL-17 inhibitors and oral JAK inhibitors such as AbbVie’s Rinvoq (and Pfizer’s Xeljanz for AS).
Questions answered:
- How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
- What are experts’ insights on current treatment options for AS and nr-AxSpA? What clinical needs remain unfulfilled?
- What pipeline products are the most promising, and what key therapies are in early-phase development?
- What are experts’ opinions of the use of Bimzelx, Xeljanz and Rinvoq for AS? What sales / uptake could non-TNF therapies secure in AxSpA?
- What are the drivers of and constraints in the AxSpA therapy market, and how will the market evolve over the forecast period?
Content highlights:
Geographies: United States, EU5, Japan
Primary research: Country-specific interviews with thought-leading rheumatologists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalent cases of AxSpA by country; AS and nr-AxSpA subpopulations.
Forecast: 10-year, annualized, drug-level sales and patient share of key AxSpA therapies through 2035, segmented by brands / generics and epidemiological subpopulations
Drug treatments: Coverage of key current and late-phase emerging therapies
Product description: Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
Table of contents
- Axial Spondyloarthritis - Landscape & Forecast - Disease Landscape & Forecast (Major Markets)
- Executive Summary
- Key Updates
- Market Forecast
- Disease Context
- Epidemiology
- Current Treatment
- Emerging Therapies
- Drug Pipeline
- Appendix
- Executive Summary